Advertisement

Index by author

August 01, 1991; Volume 258,Issue 2

A

  1. Adeagbo, A S

    1. Contribution of K+ channels to arachidonic acid-induced endothelium-dependent vasodilation in rat isolated perfused mesenteric arteries.
      A S Adeagbo and K U Malik
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 452-458;

  2. Andersson, R G

    1. Antagonistic effect of amiloride on alpha-2 adrenoceptor-mediated pigment aggregation: pharmacological heterogeneity between B-HT 920 and noradrenaline.
      S P Svensson, L G Mårtensson, N Grundström, R G Andersson, E J Cragoe and J O Karlsson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 447-451;

  3. Arzubiaga, C

    1. Caffeine and theophylline as adenosine receptor antagonists in humans.
      I Biaggioni, S Paul, A Puckett and C Arzubiaga
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 588-593;

B

  1. Bakry, N

    1. Tetanus toxin and neuronal membranes: the relationship between binding and toxicity.
      N Bakry, Y Kamata, R Sorensen and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 613-619;

  2. Barajas-Lopez, C

    1. Adenosine A1 and A2 receptors mediate presynaptic inhibition and postsynaptic excitation in guinea pig submucosal neurons.
      C Barajas-Lopez, A Surprenant and R A North
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 490-495;

  3. Beani, L

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  4. Beaujouan, J C

    1. Inhibitory effects of substance P and carbachol on the saturable sodium-dependent uptake process of myo-inositol in rat parotid gland.
      Y Torrens, M Dietl, J C Beaujouan and J Glowinski
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 639-646;

  5. Berry, B W

    1. Presystemic and systemic chiral inversion of R-(-)-fenoprofen in the rat.
      B W Berry and F Jamali
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 695-701;

  6. Bertani, T

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;

  7. Bhargava, H N

    1. Analgesic and hyperthermic effects of intravenously administered morphine in the rat are related to its serum levels.
      H N Bhargava, V M Villar, A Gulati and G Chari
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 511-516;

  8. Biaggioni, I

    1. Caffeine and theophylline as adenosine receptor antagonists in humans.
      I Biaggioni, S Paul, A Puckett and C Arzubiaga
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 588-593;

  9. Bianchi, C

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  10. Black, S C

    1. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
      S C Black, L G Chi, D X Mu and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 416-423;

  11. Boccardo, P

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;

  12. Braughler, J M

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  13. Buccafusco, J J

    1. Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats.
      K Elrod and J J Buccafusco
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 403-409;

  14. Buxton, I L

    1. Action of adenosine in estrogen-primed nonpregnant guinea pig myometrium: characterization of the smooth muscle receptor and coupling to phosphoinositide metabolism.
      W P Schiemann, K O Doggwiler and I L Buxton
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 429-437;

C

  1. Carpenter-Deyo, L

    1. Toxicity to isolated hepatocytes caused by the intracellular calcium indicator, Quin 2.
      L Carpenter-Deyo, J R Duimstra, O Hedstrom and D J Reed
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 739-746;
    2. Involvement of calcium and iron in Quin 2 toxicity to isolated hepatocytes.
      L Carpenter-Deyo and D J Reed
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 747-752;

  2. Cavero, I

    1. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
      A Floch, L Tahraoui, P Sedivy and I Cavero
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 567-575;

  3. Chan, J

    1. Endothelin and calcium signaling in NG108-15 neuroblastoma x glioma cells.
      J Chan and D A Greenberg
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 524-530;

  4. Chari, G

    1. Analgesic and hyperthermic effects of intravenously administered morphine in the rat are related to its serum levels.
      H N Bhargava, V M Villar, A Gulati and G Chari
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 511-516;

  5. Cheng, J B

    1. Competition of leukotrienes and ICI-198,615 for [3H]LTD4 binding sites in guinea pig lung membranes suggests the involvement of two LTD4 receptor subtypes.
      J T Shirley and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 531-536;

  6. Chi, L G

    1. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
      S C Black, L G Chi, D X Mu and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 416-423;

  7. Christensen, B

    1. Interaction between methotrexate, "rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture.
      H Refsum, B Christensen, R Djurhuus and P M Ueland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 559-566;

  8. Cox, D A

    1. Identification of a 17-kDa protein associated with the peripheral-type benzodiazepine receptor in vascular and other smooth muscle types.
      D A Cox, P T Ellinor, T L Kirley and M A Matlib
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 702-709;

  9. Cozzi, N V

    1. Age-related differences in the effects of some muscarinic agents on acetylcholine release from rat neostriatal slices.
      H J Lee, N V Cozzi and M H Weiler
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 496-501;

  10. Cragoe, E J

    1. Antagonistic effect of amiloride on alpha-2 adrenoceptor-mediated pigment aggregation: pharmacological heterogeneity between B-HT 920 and noradrenaline.
      S P Svensson, L G Mårtensson, N Grundström, R G Andersson, E J Cragoe and J O Karlsson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 447-451;

D

  1. Delanney, L E

    1. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
      D A Di Monte, E Y Wu, I Irwin, L E Delanney and J W Langston
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 594-600;

  2. Delansorne, R

    1. Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro.
      V Dorai, M C Hazard, J Paris and R Delansorne
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 620-625;

  3. Dietl, M

    1. Inhibitory effects of substance P and carbachol on the saturable sodium-dependent uptake process of myo-inositol in rat parotid gland.
      Y Torrens, M Dietl, J C Beaujouan and J Glowinski
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 639-646;

  4. Di Monte, D A

    1. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
      D A Di Monte, E Y Wu, I Irwin, L E Delanney and J W Langston
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 594-600;

  5. Djurhuus, R

    1. Interaction between methotrexate, "rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture.
      H Refsum, B Christensen, R Djurhuus and P M Ueland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 559-566;

  6. Doggwiler, K O

    1. Action of adenosine in estrogen-primed nonpregnant guinea pig myometrium: characterization of the smooth muscle receptor and coupling to phosphoinositide metabolism.
      W P Schiemann, K O Doggwiler and I L Buxton
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 429-437;

  7. Dorai, V

    1. Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro.
      V Dorai, M C Hazard, J Paris and R Delansorne
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 620-625;

  8. Duimstra, J R

    1. Toxicity to isolated hepatocytes caused by the intracellular calcium indicator, Quin 2.
      L Carpenter-Deyo, J R Duimstra, O Hedstrom and D J Reed
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 739-746;

  9. Durcan, M J

    1. Evidence for central alpha-2 adrenoceptors, not imidazoline binding sites, mediating the ethanol-attenuating properties of alpha-2 adrenoceptor antagonists.
      M J Durcan, R G Lister and M Linnoila
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 576-582;

E

  1. Edeson, R O

    1. Naltrexone modulation of nicotinic acetylcholine receptor activity.
      A C Le Dain, B W Madsen and R O Edeson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 551-558;

  2. Ellinor, P T

    1. Identification of a 17-kDa protein associated with the peripheral-type benzodiazepine receptor in vascular and other smooth muscle types.
      D A Cox, P T Ellinor, T L Kirley and M A Matlib
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 702-709;

  3. Elrod, K

    1. Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats.
      K Elrod and J J Buccafusco
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 403-409;

F

  1. Ferraro, L

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  2. Floch, A

    1. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
      A Floch, L Tahraoui, P Sedivy and I Cavero
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 567-575;

  3. Folger, W H

    1. Response of rat thoracic aortic rings to thromboxane mimetic U-46,619: roles of endothelium-derived relaxing factor and thromboxane A2 release.
      W H Folger, D Lawson, C S Wilcox and J L Mehta
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 669-675;

  4. Formby, B

    1. Studies of concanavalin A in nonobese diabetic mice. II. Lymphocyte tracking and phenotype responses.
      B Mukherjee, R B Pearce, B Formby and C M Peterson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 716-721;

  5. France, C P

    1. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
      C P France, G Winger, F Medzihradsky, M R Seggel, K C Rice and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 502-510;

G

  1. Gillis, A M

    1. Propafenone disposition and pharmacodynamics in normal and norepinephrine-induced cardiomyopathic rabbit hearts.
      A M Gillis, W M Lester and R Keashly
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 722-727;

  2. Glowinski, J

    1. Inhibitory effects of substance P and carbachol on the saturable sodium-dependent uptake process of myo-inositol in rat parotid gland.
      Y Torrens, M Dietl, J C Beaujouan and J Glowinski
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 639-646;
    2. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization.
      R Godbout, J Mantz, S Pirot, J Glowinski and A M Thierry
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 728-738;

  3. Godbout, R

    1. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization.
      R Godbout, J Mantz, S Pirot, J Glowinski and A M Thierry
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 728-738;

  4. Goshima, Y

    1. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
      Y Goshima, S Nakamura and Y Misu
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 466-471;

  5. Greenberg, D A

    1. Endothelin and calcium signaling in NG108-15 neuroblastoma x glioma cells.
      J Chan and D A Greenberg
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 524-530;

  6. Grundemar, L

    1. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem.
      L Grundemar, C Wahlestedt and D J Reis
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 633-638;

  7. Grundström, N

    1. Antagonistic effect of amiloride on alpha-2 adrenoceptor-mediated pigment aggregation: pharmacological heterogeneity between B-HT 920 and noradrenaline.
      S P Svensson, L G Mårtensson, N Grundström, R G Andersson, E J Cragoe and J O Karlsson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 447-451;

  8. Guerrant, R L

    1. Purified choleragenoid does not induce migrating action potential complex activity in rabbit ileum in vivo.
      C D Lind, R L Guerrant, A Kurosky and J R Mathias
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 647-651;

  9. Gulati, A

    1. Analgesic and hyperthermic effects of intravenously administered morphine in the rat are related to its serum levels.
      H N Bhargava, V M Villar, A Gulati and G Chari
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 511-516;

H

  1. Halenda, S P

    1. Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells.
      H Wu, J T Turner and S P Halenda
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 607-612;

  2. Hall, E D

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  3. Hazard, M C

    1. Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro.
      V Dorai, M C Hazard, J Paris and R Delansorne
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 620-625;

  4. Healy, D P

    1. [3H]domperidone binding to the kidney inner medullary collecting duct dopamine-2K (DA2K) receptor.
      T Huo and D P Healy
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 424-428;

  5. Hedstrom, O

    1. Toxicity to isolated hepatocytes caused by the intracellular calcium indicator, Quin 2.
      L Carpenter-Deyo, J R Duimstra, O Hedstrom and D J Reed
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 739-746;

  6. Henstenberg, J D

    1. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
      G C Yaney, G A Stafford, J D Henstenberg, G W Sharp and G A Weiland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 652-662;

  7. Huo, T

    1. [3H]domperidone binding to the kidney inner medullary collecting duct dopamine-2K (DA2K) receptor.
      T Huo and D P Healy
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 424-428;

I

  1. Irwin, I

    1. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
      D A Di Monte, E Y Wu, I Irwin, L E Delanney and J W Langston
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 594-600;

J

  1. Jacobsen, E J

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  2. Jamali, F

    1. Presystemic and systemic chiral inversion of R-(-)-fenoprofen in the rat.
      B W Berry and F Jamali
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 695-701;

K

  1. Kamata, Y

    1. Tetanus toxin and neuronal membranes: the relationship between binding and toxicity.
      N Bakry, Y Kamata, R Sorensen and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 613-619;

  2. Kanda, M

    1. Effect of accumulation of NKY-722, a water-soluble vasoselective Ca++ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries.
      H Shimaji, H Shirahase, M Kanda, S Osumi and K Kurahashi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 676-680;

  3. Karlsson, J O

    1. Antagonistic effect of amiloride on alpha-2 adrenoceptor-mediated pigment aggregation: pharmacological heterogeneity between B-HT 920 and noradrenaline.
      S P Svensson, L G Mårtensson, N Grundström, R G Andersson, E J Cragoe and J O Karlsson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 447-451;

  4. Keashly, R

    1. Propafenone disposition and pharmacodynamics in normal and norepinephrine-induced cardiomyopathic rabbit hearts.
      A M Gillis, W M Lester and R Keashly
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 722-727;

  5. Kirley, T L

    1. Identification of a 17-kDa protein associated with the peripheral-type benzodiazepine receptor in vascular and other smooth muscle types.
      D A Cox, P T Ellinor, T L Kirley and M A Matlib
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 702-709;

  6. Kurahashi, K

    1. Effect of accumulation of NKY-722, a water-soluble vasoselective Ca++ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries.
      H Shimaji, H Shirahase, M Kanda, S Osumi and K Kurahashi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 676-680;

  7. Kurosky, A

    1. Purified choleragenoid does not induce migrating action potential complex activity in rabbit ileum in vivo.
      C D Lind, R L Guerrant, A Kurosky and J R Mathias
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 647-651;

L

  1. Lahti, R A

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  2. Langston, J W

    1. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
      D A Di Monte, E Y Wu, I Irwin, L E Delanney and J W Langston
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 594-600;

  3. Lawson, D

    1. Response of rat thoracic aortic rings to thromboxane mimetic U-46,619: roles of endothelium-derived relaxing factor and thromboxane A2 release.
      W H Folger, D Lawson, C S Wilcox and J L Mehta
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 669-675;

  4. Le Dain, A C

    1. Naltrexone modulation of nicotinic acetylcholine receptor activity.
      A C Le Dain, B W Madsen and R O Edeson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 551-558;

  5. Lee, H J

    1. Age-related differences in the effects of some muscarinic agents on acetylcholine release from rat neostriatal slices.
      H J Lee, N V Cozzi and M H Weiler
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 496-501;

  6. Lee, J H

    1. A WB 4101-sensitive alpha-1 adrenergic receptor subtype modulates repolarization in canine Purkinje fibers.
      J H Lee, S F Steinberg and M R Rosen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 681-687;

  7. Lester, W M

    1. Propafenone disposition and pharmacodynamics in normal and norepinephrine-induced cardiomyopathic rabbit hearts.
      A M Gillis, W M Lester and R Keashly
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 722-727;

  8. Lichtman, A H

    1. Spinal and supraspinal components of cannabinoid-induced antinociception.
      A H Lichtman and B R Martin
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 517-523;

  9. Lind, C D

    1. Purified choleragenoid does not induce migrating action potential complex activity in rabbit ileum in vivo.
      C D Lind, R L Guerrant, A Kurosky and J R Mathias
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 647-651;

  10. Linnoila, M

    1. Evidence for central alpha-2 adrenoceptors, not imidazoline binding sites, mediating the ethanol-attenuating properties of alpha-2 adrenoceptor antagonists.
      M J Durcan, R G Lister and M Linnoila
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 576-582;

  11. Linseman, K L

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  12. Lister, R G

    1. Evidence for central alpha-2 adrenoceptors, not imidazoline binding sites, mediating the ethanol-attenuating properties of alpha-2 adrenoceptor antagonists.
      M J Durcan, R G Lister and M Linnoila
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 576-582;

  13. Löscher, W

    1. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats.
      W Löscher and C Rundfeldt
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 483-489;

  14. Lucchesi, B R

    1. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
      S C Black, L G Chi, D X Mu and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 416-423;

M

  1. Macconi, D

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;

  2. Madsen, B W

    1. Naltrexone modulation of nicotinic acetylcholine receptor activity.
      A C Le Dain, B W Madsen and R O Edeson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 551-558;

  3. Malik, K U

    1. Contribution of K+ channels to arachidonic acid-induced endothelium-dependent vasodilation in rat isolated perfused mesenteric arteries.
      A S Adeagbo and K U Malik
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 452-458;

  4. Mantz, J

    1. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization.
      R Godbout, J Mantz, S Pirot, J Glowinski and A M Thierry
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 728-738;

  5. Mårtensson, L G

    1. Antagonistic effect of amiloride on alpha-2 adrenoceptor-mediated pigment aggregation: pharmacological heterogeneity between B-HT 920 and noradrenaline.
      S P Svensson, L G Mårtensson, N Grundström, R G Andersson, E J Cragoe and J O Karlsson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 447-451;

  6. Martin, B R

    1. Spinal and supraspinal components of cannabinoid-induced antinociception.
      A H Lichtman and B R Martin
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 517-523;

  7. Mathias, J R

    1. Purified choleragenoid does not induce migrating action potential complex activity in rabbit ileum in vivo.
      C D Lind, R L Guerrant, A Kurosky and J R Mathias
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 647-651;

  8. Matlib, M A

    1. Identification of a 17-kDa protein associated with the peripheral-type benzodiazepine receptor in vascular and other smooth muscle types.
      D A Cox, P T Ellinor, T L Kirley and M A Matlib
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 702-709;

  9. Mattia, A

    1. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes.
      A Mattia, T Vanderah, H I Mosberg and F Porreca
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 583-587;

  10. Means, E D

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  11. Medzihradsky, F

    1. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
      C P France, G Winger, F Medzihradsky, M R Seggel, K C Rice and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 502-510;

  12. Mehta, J L

    1. Response of rat thoracic aortic rings to thromboxane mimetic U-46,619: roles of endothelium-derived relaxing factor and thromboxane A2 release.
      W H Folger, D Lawson, C S Wilcox and J L Mehta
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 669-675;

  13. Meijer, D K

    1. Mechanisms for the uptake of cationic drugs by the liver: a study with tributylmethylammonium (TBuMA).
      H Steen, R Oosting and D K Meijer
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 537-543;

  14. Melia, K F

    1. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909.
      K F Melia and R D Spealman
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 626-632;

  15. Misu, Y

    1. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
      Y Goshima, S Nakamura and Y Misu
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 466-471;

  16. Mjanger, E

    1. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
      E Mjanger and T L Yaksh
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 544-550;

  17. Morari, M

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  18. Morigi, M

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;

  19. Mosberg, H I

    1. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes.
      A Mattia, T Vanderah, H I Mosberg and F Porreca
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 583-587;

  20. Mu, D X

    1. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
      S C Black, L G Chi, D X Mu and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 416-423;

  21. Mukherjee, B

    1. Studies of concanavalin A in nonobese diabetic mice. II. Lymphocyte tracking and phenotype responses.
      B Mukherjee, R B Pearce, B Formby and C M Peterson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 716-721;

N

  1. Nakamura, S

    1. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
      Y Goshima, S Nakamura and Y Misu
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 466-471;

  2. Nishimura, J

    1. Energetic aspects of the regulation of Ca++ sensitivity of permeabilized rabbit mesenteric artery: possible involvement of a second Ca++ regulatory system in smooth muscle contraction.
      J Nishimura and C van Breemen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 397-402;

  3. North, R A

    1. Adenosine A1 and A2 receptors mediate presynaptic inhibition and postsynaptic excitation in guinea pig submucosal neurons.
      C Barajas-Lopez, A Surprenant and R A North
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 490-495;
    2. Baclofen and adenosine inhibit synaptic potentials mediated by gamma-aminobutyric acid and glutamate release in rat nucleus accumbens.
      N Uchimura and R A North
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 663-668;

O

  1. Ohnishi, T

    1. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier.
      T Shimura, S Tabata, T Ohnishi, T Terasaki and A Tsuji
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 459-465;

  2. Olsen, G D

    1. Cocaine pharmacokinetics in the pregnant guinea pig.
      J A Sandberg and G D Olsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 477-482;

  3. Oosting, R

    1. Mechanisms for the uptake of cationic drugs by the liver: a study with tributylmethylammonium (TBuMA).
      H Steen, R Oosting and D K Meijer
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 537-543;

  4. Osumi, S

    1. Effect of accumulation of NKY-722, a water-soluble vasoselective Ca++ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries.
      H Shimaji, H Shirahase, M Kanda, S Osumi and K Kurahashi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 676-680;

P

  1. Paris, J

    1. Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro.
      V Dorai, M C Hazard, J Paris and R Delansorne
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 620-625;

  2. Paul, S

    1. Caffeine and theophylline as adenosine receptor antagonists in humans.
      I Biaggioni, S Paul, A Puckett and C Arzubiaga
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 588-593;

  3. Pearce, R B

    1. Studies of concanavalin A in nonobese diabetic mice. I. Prevention of insulin-dependent diabetes.
      R B Pearce and C M Peterson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 710-715;
    2. Studies of concanavalin A in nonobese diabetic mice. II. Lymphocyte tracking and phenotype responses.
      B Mukherjee, R B Pearce, B Formby and C M Peterson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 716-721;

  4. Peterson, C M

    1. Studies of concanavalin A in nonobese diabetic mice. I. Prevention of insulin-dependent diabetes.
      R B Pearce and C M Peterson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 710-715;
    2. Studies of concanavalin A in nonobese diabetic mice. II. Lymphocyte tracking and phenotype responses.
      B Mukherjee, R B Pearce, B Formby and C M Peterson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 716-721;

  5. Pirot, S

    1. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization.
      R Godbout, J Mantz, S Pirot, J Glowinski and A M Thierry
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 728-738;

  6. Porreca, F

    1. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes.
      A Mattia, T Vanderah, H I Mosberg and F Porreca
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 583-587;

  7. Puckett, A

    1. Caffeine and theophylline as adenosine receptor antagonists in humans.
      I Biaggioni, S Paul, A Puckett and C Arzubiaga
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 588-593;

R

  1. Reed, D J

    1. Toxicity to isolated hepatocytes caused by the intracellular calcium indicator, Quin 2.
      L Carpenter-Deyo, J R Duimstra, O Hedstrom and D J Reed
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 739-746;
    2. Involvement of calcium and iron in Quin 2 toxicity to isolated hepatocytes.
      L Carpenter-Deyo and D J Reed
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 747-752;

  2. Refsum, H

    1. Interaction between methotrexate, "rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture.
      H Refsum, B Christensen, R Djurhuus and P M Ueland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 559-566;

  3. Reis, D J

    1. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem.
      L Grundemar, C Wahlestedt and D J Reis
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 633-638;

  4. Remuzzi, G

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;

  5. Riccardi, E

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;

  6. Rice, K C

    1. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
      C P France, G Winger, F Medzihradsky, M R Seggel, K C Rice and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 502-510;

  7. Rosen, M R

    1. A WB 4101-sensitive alpha-1 adrenergic receptor subtype modulates repolarization in canine Purkinje fibers.
      J H Lee, S F Steinberg and M R Rosen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 681-687;

  8. Rundfeldt, C

    1. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats.
      W Löscher and C Rundfeldt
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 483-489;

S

  1. Sandberg, J A

    1. Cocaine pharmacokinetics in the pregnant guinea pig.
      J A Sandberg and G D Olsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 477-482;

  2. Scherch, H M

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  3. Schiemann, W P

    1. Action of adenosine in estrogen-primed nonpregnant guinea pig myometrium: characterization of the smooth muscle receptor and coupling to phosphoinositide metabolism.
      W P Schiemann, K O Doggwiler and I L Buxton
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 429-437;

  4. Sedivy, P

    1. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
      A Floch, L Tahraoui, P Sedivy and I Cavero
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 567-575;

  5. Seggel, M R

    1. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
      C P France, G Winger, F Medzihradsky, M R Seggel, K C Rice and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 502-510;

  6. Sharp, G W

    1. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
      G C Yaney, G A Stafford, J D Henstenberg, G W Sharp and G A Weiland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 652-662;

  7. Shimaji, H

    1. Effect of accumulation of NKY-722, a water-soluble vasoselective Ca++ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries.
      H Shimaji, H Shirahase, M Kanda, S Osumi and K Kurahashi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 676-680;

  8. Shimura, T

    1. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier.
      T Shimura, S Tabata, T Ohnishi, T Terasaki and A Tsuji
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 459-465;

  9. Shirahase, H

    1. Effect of accumulation of NKY-722, a water-soluble vasoselective Ca++ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries.
      H Shimaji, H Shirahase, M Kanda, S Osumi and K Kurahashi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 676-680;

  10. Shirley, J T

    1. Competition of leukotrienes and ICI-198,615 for [3H]LTD4 binding sites in guinea pig lung membranes suggests the involvement of two LTD4 receptor subtypes.
      J T Shirley and J B Cheng
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 531-536;

  11. Simonato, M

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  12. Simpson, L L

    1. Tetanus toxin and neuronal membranes: the relationship between binding and toxicity.
      N Bakry, Y Kamata, R Sorensen and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 613-619;

  13. Smith, S L

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

  14. Smith, T L

    1. Selective effects of acute and chronic ethanol exposure on neuropeptide and guanine nucleotide stimulated phospholipase C activity in intact N1E-115 neuroblastoma.
      T L Smith
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 410-415;

  15. Sorensen, R

    1. Tetanus toxin and neuronal membranes: the relationship between binding and toxicity.
      N Bakry, Y Kamata, R Sorensen and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 613-619;

  16. Spalluto, G

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  17. Spealman, R D

    1. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909.
      K F Melia and R D Spealman
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 626-632;

  18. Stafford, G A

    1. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
      G C Yaney, G A Stafford, J D Henstenberg, G W Sharp and G A Weiland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 652-662;

  19. Steen, H

    1. Mechanisms for the uptake of cationic drugs by the liver: a study with tributylmethylammonium (TBuMA).
      H Steen, R Oosting and D K Meijer
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 537-543;

  20. Steinberg, S F

    1. A WB 4101-sensitive alpha-1 adrenergic receptor subtype modulates repolarization in canine Purkinje fibers.
      J H Lee, S F Steinberg and M R Rosen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 681-687;

  21. Surprenant, A

    1. Adenosine A1 and A2 receptors mediate presynaptic inhibition and postsynaptic excitation in guinea pig submucosal neurons.
      C Barajas-Lopez, A Surprenant and R A North
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 490-495;

  22. Svensson, S P

    1. Antagonistic effect of amiloride on alpha-2 adrenoceptor-mediated pigment aggregation: pharmacological heterogeneity between B-HT 920 and noradrenaline.
      S P Svensson, L G Mårtensson, N Grundström, R G Andersson, E J Cragoe and J O Karlsson
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 447-451;

T

  1. Tabata, S

    1. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier.
      T Shimura, S Tabata, T Ohnishi, T Terasaki and A Tsuji
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 459-465;

  2. Tahraoui, L

    1. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
      A Floch, L Tahraoui, P Sedivy and I Cavero
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 567-575;

  3. Takano, Y

    1. Relative efficacy of spinal alpha-2 agonists, dexmedetomidine, clonidine and ST-91, determined in vivo by using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible antagonist.
      Y Takano and T L Yaksh
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 438-446;

  4. Tanganelli, S

    1. Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance.
      L Beani, C Bianchi, L Ferraro, M Morari, M Simonato, G Spalluto and S Tanganelli
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 472-476;

  5. Terasaki, T

    1. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier.
      T Shimura, S Tabata, T Ohnishi, T Terasaki and A Tsuji
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 459-465;

  6. Thierry, A M

    1. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization.
      R Godbout, J Mantz, S Pirot, J Glowinski and A M Thierry
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 728-738;

  7. Torrens, Y

    1. Inhibitory effects of substance P and carbachol on the saturable sodium-dependent uptake process of myo-inositol in rat parotid gland.
      Y Torrens, M Dietl, J C Beaujouan and J Glowinski
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 639-646;

  8. Tsuji, A

    1. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier.
      T Shimura, S Tabata, T Ohnishi, T Terasaki and A Tsuji
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 459-465;

  9. Turner, J T

    1. Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells.
      H Wu, J T Turner and S P Halenda
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 607-612;

U

  1. Uchimura, N

    1. Baclofen and adenosine inhibit synaptic potentials mediated by gamma-aminobutyric acid and glutamate release in rat nucleus accumbens.
      N Uchimura and R A North
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 663-668;

  2. Ueland, P M

    1. Interaction between methotrexate, "rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture.
      H Refsum, B Christensen, R Djurhuus and P M Ueland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 559-566;

V

  1. van Breemen, C

    1. Energetic aspects of the regulation of Ca++ sensitivity of permeabilized rabbit mesenteric artery: possible involvement of a second Ca++ regulatory system in smooth muscle contraction.
      J Nishimura and C van Breemen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 397-402;

  2. Vanderah, T

    1. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes.
      A Mattia, T Vanderah, H I Mosberg and F Porreca
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 583-587;

  3. Villar, V M

    1. Analgesic and hyperthermic effects of intravenously administered morphine in the rat are related to its serum levels.
      H N Bhargava, V M Villar, A Gulati and G Chari
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 511-516;

  4. Von Voigtlander, P F

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

W

  1. Wahlestedt, C

    1. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem.
      L Grundemar, C Wahlestedt and D J Reis
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 633-638;

  2. Weiland, G A

    1. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
      G C Yaney, G A Stafford, J D Henstenberg, G W Sharp and G A Weiland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 652-662;

  3. Weiler, M H

    1. Age-related differences in the effects of some muscarinic agents on acetylcholine release from rat neostriatal slices.
      H J Lee, N V Cozzi and M H Weiler
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 496-501;

  4. Wilcox, C S

    1. Response of rat thoracic aortic rings to thromboxane mimetic U-46,619: roles of endothelium-derived relaxing factor and thromboxane A2 release.
      W H Folger, D Lawson, C S Wilcox and J L Mehta
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 669-675;

  5. Winger, G

    1. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
      C P France, G Winger, F Medzihradsky, M R Seggel, K C Rice and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 502-510;

  6. Woods, J H

    1. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
      C P France, G Winger, F Medzihradsky, M R Seggel, K C Rice and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 502-510;

  7. Wu, E Y

    1. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
      D A Di Monte, E Y Wu, I Irwin, L E Delanney and J W Langston
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 594-600;

  8. Wu, H

    1. Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells.
      H Wu, J T Turner and S P Halenda
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 607-612;

Y

  1. Yaksh, T L

    1. Relative efficacy of spinal alpha-2 agonists, dexmedetomidine, clonidine and ST-91, determined in vivo by using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible antagonist.
      Y Takano and T L Yaksh
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 438-446;
    2. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
      E Mjanger and T L Yaksh
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 544-550;

  2. Yaney, G C

    1. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
      G C Yaney, G A Stafford, J D Henstenberg, G W Sharp and G A Weiland
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 652-662;

  3. Yonkers, P A

    1. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.
      E D Hall, J M Braughler, P A Yonkers, S L Smith, K L Linseman, E D Means, H M Scherch, P F Von Voigtlander, R A Lahti and E J Jacobsen
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 688-694;

Z

  1. Zilio, P

    1. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice.
      M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi
      Journal of Pharmacology and Experimental Therapeutics August 1991, 258 (2) 601-606;
Back to top

In this issue